Is romigrastim currently included in medical insurance?

Romiplostim is a thrombopoietin receptor agonist used to treat diseases such as chronic immune thrombocytopenia (ITP). The drug helps patients restore platelet levels and reduce the risk of bleeding by promoting the proliferation and differentiation of megakaryocytes in the bone marrow. In recent years, with the development of medical technology, romiplostim has been successfully launched in China, providing patients with more treatment options.

At present, romiplostim has been included in China's medical insurance system, which means that patients can enjoy preferential policies for medical insurance reimbursement when using this drug, which greatly reduces the financial burden of patients. The inclusion in medical insurance not only reflects the country's recognition of the efficacy and safety of the drug, but also makes it easier for more patients in need of treatment to afford such high-priced drugs.

In terms of price, the price of imported romigrastim in the domestic market is about more than 2,000 yuan per pill, while the price of the domestic version is relatively affordable, about more than 1,000 yuan per pill. The specific costs and medical insurance reimbursement ratios may vary depending on the region and hospital. Patients should consult the local hospital pharmacy when purchasing to ensure accurate price and reimbursement information.

Overall, the launch of romiplostim and its inclusion in medical insurance have greatly improved the accessibility of treatment for patients with chronic immune thrombocytopenia. Patients should use it rationally under the guidance of professional doctors and pay attention to changes in medical insurance policies to obtain the best therapeutic effect and financial support.

Reference: https://en.wikipedia.org/wiki/Romiplostim